EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Role of IRF9 Upregulation in Modulating Sensitivity to Olaparib and Platinum-Based Chemotherapies in Breast Cancer

SeokGyeong Choi, Han-Gyu Bae iD, Dong-Gyu Jo iD, Woo-Young Kim

Genes · 2024

DOI: 10.3390/genes15070959 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2024. Verfasst von SeokGyeong Choi und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Sookmyung Women's University, Seoul 04310, Republic of Korea. Hauptthemen laut MEDLINE: Phthalazines, Piperazines, Breast Neoplasms, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute, National Research Foundation of Korea, Health Fellowship Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poly(ADP-ribose) polymerase (PARP) inhibitors are targeted therapies that accumulate DNA damage by interfering with DNA repair mechanisms and are approved for treating several cancers with BRCA1/2 mutations. In this study, we utilized CRISPR-dCas9 interference screening to identify genes regulating sensitivity to PARP inhibitors in breast cancer cell lines. Our findings indicated that the interferon (IFN) signaling gene IRF9 was critically involved in modulating sensitivity to these inhibitors. We revealed that the loss of IRF9 leads to increased resistance to the PARP inhibitor in MDA-MB-468 cells, and a similar desensitization was observed in another breast cancer cell line, MDA-MB-231. Further analysis indicated that while the basal expression of IRF9 did not correlate with the response to the PARP inhibitor olaparib, its transcriptional induction was significantly associated with increased sensitivity to the DNA-damaging agent cisplatin in the NCI-60 cell line panel. This finding suggests a mechanistic link between IRF9 induction and cellular responses to DNA damage. Additionally, data from the METABRIC patient tissue study revealed a complex network of IFN-responsive gene expressions postchemotherapy, with seven upregulated genes, including IRF9, and three downregulated genes. These findings underscore the intricate role of IFN signaling in the cellular response to chemotherapy. Collectively, our CRISPR screening data and subsequent bioinformatic analyses suggest that IRF9 is a novel biomarker for sensitivity to DNA-damaging agents, such as olaparib and platinum-based chemotherapeutic agents. Our findings for IRF9 not only enhance our understanding of the genetic basis of drug sensitivity, but also elucidate the role of IRF9 as a critical effector within IFN signaling pathways, potentially influencing the association between the host immune system and chemotherapeutic efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhthalazinesPiperazinesBreast NeoplasmsGene Expression Regulation, NeoplasticDrug Resistance, NeoplasmPoly(ADP-ribose) Polymerase InhibitorsInterferon-Stimulated Gene Factor 3, gamma SubunitHumansFemaleCell Line, TumorUp-RegulationCisplatinAntineoplastic AgentsDNA Damage

Stichwörter der Autor:innen

IRF9PARP inhibitorbiomarkerpatinsresistance

Substanzen

PhthalazinesolaparibPiperazinesPoly(ADP-ribose) Polymerase InhibitorsInterferon-Stimulated Gene Factor 3, gamma SubunitIRF9 protein, humanCisplatinAntineoplastic Agents

Autor:innen und Institutionen

  • College of Pharmacy, Sookmyung Women's University, Seoul 04310, Republic of Korea.
  • School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
  • Muscle Physiome Research Center, Sookmyung Women's University, Seoul 04310, Republic of Korea.
  • Drug Information Research Institute, Sookmyung Women's University, Seoul 04310, Republic of Korea.

ORCID-Profile: Han-Gyu Bae, Dong-Gyu Jo

Förderung

  • Korea Health Industry Development Institute
  • National Research Foundation of Korea
  • Health Fellowship Foundation
  • Korean government (MSIT)

Zitieren

APA

Choi, S., Bae, H. G., Jo, D. G., & Kim, W. Y. (2024). The Role of IRF9 Upregulation in Modulating Sensitivity to Olaparib and Platinum-Based Chemotherapies in Breast Cancer. Genes. https://doi.org/10.3390/genes15070959

Vancouver

Choi S, Bae HG, Jo DG, Kim WY. The Role of IRF9 Upregulation in Modulating Sensitivity to Olaparib and Platinum-Based Chemotherapies in Breast Cancer. Genes. 2024. doi:10.3390/genes15070959

BibTeX
@article{Choi2024,
  author = {Choi, SeokGyeong and Bae, Han-Gyu and Jo, Dong-Gyu and Kim, Woo-Young},
  title = {The Role of IRF9 Upregulation in Modulating Sensitivity to Olaparib and Platinum-Based Chemotherapies in Breast Cancer},
  journal = {Genes},
  year = {2024},
  doi = {10.3390/genes15070959}
}
Kostenlos starten →